A Phase 1b trial found the therapy based on research from Weizmann Institute of Science safe and well tolerated in early Alzheimer’s patients, offering preliminary support for an immune-focused approach that targets brain inflammation   | Read More in ynet – Culture.   Read More in Israel NOWlej.